Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01625936 · ClinicalTrials.gov registry record · Phase 1
CRLX101 Plus Bevacizumab in Advanced RCC
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01625936 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 22 participants.
The verdict
NCT01625936, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a Phase 1b, dose escalation study of the investigational agent, CRLX101, given in combination with Bevacizumab in patients with advanced renal cell carcinoma. The purpose of this study is to determine the initial safety and effectiveness of this agent in combination with Bevacizumab. The investigators are also trying to determine the best dose level of CRLX101 to give in combination with bevacizumab. About 22 subjects will be enrolled in this study at the University of Pennsylvania.
Interventions
- DRUG Bevacizumab
- DRUG CRLX101 (Cerulean)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-06 |
| Est. Completion | 2018-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01625936
The ClinicalTrials.gov registry entry for NCT01625936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01625936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01625936 about?
NCT01625936 is a clinical study titled "CRLX101 Plus Bevacizumab in Advanced RCC". This is a Phase 1b, dose escalation study of the investigational agent, CRLX101, given in combination with Bevacizumab in patients with advanced renal cell carcinoma. The purpose of this study is to determine the initial safety and effectiveness of this agent in combination with Bevacizumab. The inv...
What is the current status of trial NCT01625936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2012-06. Estimated completion is 2018-07-16.
What interventions are being tested in trial NCT01625936?
The interventions under investigation include: Bevacizumab (DRUG), CRLX101 (Cerulean) (DRUG).
Who is sponsoring clinical trial NCT01625936?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.